MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells

Oncotarget

Volumn 7, Issue 17, 2016, Pages 23182-23196

  Soldevilla, Mario Martínez ^a,b   Villanueva, Helena ^a,b   Casares, Noelia ^a,b   Lasarte, Juan Jose ^a,b   Bendandi, Maurizio ^c   Inoges, Susana ^b,d   de Cerio, Ascensión López Díaz ^b,d   Pastor, Fernando ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Aptamer; Cancer immunotherapy; Costimutaltion; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CD28 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MRP1 CD28 BIVALENT APTAMER; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; FEASIBILITY STUDY; HUMAN; HUMAN CELL; MALE; MELANOMA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TARGET CELL DESTRUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; APTAMERS, NUCLEOTIDE; CD28 ANTIGENS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASTIC STEM CELLS; TUMOR CELLS, CULTURED;

EID: 84966605875     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8095     Document Type: Article

References (35)

1. Nimjee SM, Rusconi CP and Sullenger BA. Aptamers: an emerging class of therapeutics. Annual review of medicine. 2005; 56:555-583.
2. Lao YH, Phua KK and Leong KW. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano. 2015; 9:2235-2254.
3. Chabner BA and Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nature reviews. 2005; 5:65-72.
4. Depeille P, Cuq P, Passagne I, Evrard A and Vian L. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer. 2005; 93:216-223.
5. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP and Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer research. 1994; 54(2):357-361.
6. Kruh GD and Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003; 22:7537-7552.
7. Young LC, Campling BG, Cole SP, Deeley RG and Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001; 7:1798-1804.
8. Faneyte IF, Kristel PM and van de Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res. 2004; 24:2931-2939.
9. Legrand O, Zittoun R and Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia. 1999; 13:578-584.
10. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258:1650-1654.
11. Alisi A, Cho WC, Locatelli F and Fruci D. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int J Mol Sci. 2013; 14:24706-24725.
12. Liu C, Li Z, Bi L, Li K, Zhou B, Xu C, Huang J and Xu K. NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells. Mol Cell Biochem. 2011; 393:265-270.
13. Moitra K, Lou H and Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 2011; 89:491-502.
14. Singh A and Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29:4741-4751.
15. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nature reviews. 2005; 5:275-284.
16. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A and Werb Z. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526:131-135.
17. Acuto O and Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nature reviews. 2003; 3:939-951.
18. Townsend SE and Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993; 259:368-370.
19. E. Small TD, W. R. Gerritsen, F. Rolland, P. Hoskin, D. C. Smith, C. Parker, D. Chondros, J. Ma, K. Hege. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium. 2009.
20. Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E and Bendandi M. CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids. 2013; 2:e98.
21. Pastor F, Kolonias D, McNamara JO, 2nd and Gilboa E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther. 2011; 19:1878-1886.
22. Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB and Gilboa E. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res. 2014; 2:867-877.
23. Rosenberg MF, Mao Q, Holzenburg A, Ford RC, Deeley RG and Cole SP. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and singleparticle analysis. The Journal of biological chemistry. 2001; 276:16076-16082.
24. He SM, Li R, Kanwar JR and Zhou SF. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem. 2011; 18:439-481.
25. Muller M, Yong M, Peng XH, Petre B, Arora S and Ambudkar SV. Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry. 2002; 41:10123-10132.
26. Alam KK, Chang JL and Burke DH. FASTAptamer: A Bioinformatic Toolkit for High-throughput Sequence Analysis of Combinatorial Selections. Mol Ther Nucleic Acids. 2015; 4:e230.
27. Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, Lopez-Sagaseta J, Guembe L, Sarobe P, Prieto J, Borras-Cuesta F and Lasarte JJ. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol. 2010; 185:5150-5159.
28. Zhang JT. Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res. 2007; 17:311-323.
29. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G and Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res. 2003; 9:827-836.
30. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS and Turka LA. An obligate cell-intrinsic function for CD28 in Tregs. The Journal of clinical investigation. 2013; 123:580-593.
31. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E and Sullenger BA. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chemistry & biology. 2008; 15:675-682.
32. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B and Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. The Journal of clinical investigation. 2008; 118:376-386.
33. Soldevilla MM, Villanueva H, Bendandi M, Inoges S, Lopez-Diaz de Cerio A and Pastor F. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials. 2015; 67:274-285.
34. Gangadhar TC and Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014; 11:91-99.
35. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373:23-34.